Intercept: 'Serious liver injury' cases on Ocaliva lead FDA to call for monitoring

Intercept: Complete Response Letter for Ocaliva (obeticholic acid, OCA) for primary biliary cholangitis

Intercept: Intercept loses Ocaliva FDA full approval bid in rare liver disease

Intercept: FDA pushes back PDUFA dates for Amgen and Intercept

Press Release: Intercept : Intercept Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept: Company Statement on FDA Advisory Committee Meeting

Intercept: FDA is poised to pull Ocaliva as adcomm documents question post-approval study results

Intercept: BRIEF---EMA recommends revoking conditional authorization for Ocaliva

Press Release: Intercept : Intercept Presents New Data on the Results of OCA-Bezafibrate Combination Therapy in PBC After Six Months of Treatment in Late-Breaking Poster Presentation at EASL Congress 2024

Press Release: Intercept : Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva (obeticholic acid) for the Treatment of PBC